|Mr. Said Samih Taleb Darwazah||Exec. Chairman||3.05M||N/A||1957|
|Mr. Sigurdur Oli Olafsson Ph.D.||CEO & Exec. Director||4.12M||N/A||1969|
|Mr. Mazen Samih Taleb Darwazah||Exec. Vice Chairman & Pres of MENA||2.18M||N/A||1958|
|Mr. Khalid Waleed Hosny Al Nabilsi||Chief Financial Officer||N/A||N/A||1972|
|Dr. Shahin Fesharaki||Chief Scientific Officer & Global Head of Research Devel.||N/A||N/A||N/A|
|Mr. Hussein Arkhagha||Chief Counsel||N/A||N/A||N/A|
|Mr. Bassam Wael Rushdi Kanaan||Exec. VP of Corp. Devel. and M&A||N/A||N/A||1965|
|Ms. Susan Ringdal||Exec. VP of Strategic Planning & Global Affairs||N/A||N/A||N/A|
|Ms. Majda Labadi||Exec. VP of Organisational Devel.||N/A||N/A||N/A|
|Mr. Riad Mishlawi||Pres of Injectables||N/A||N/A||N/A|
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals PLC’s ISS Governance QualityScore as of November 1, 2019 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 5.